The TROFFi trial represents a groundbreaking application of senolytic therapy, testing whether fisetin at 20 mg/kg daily can reverse chemotherapy-induced physical decline in 88 postmenopausal breast cancer survivors. Participants with 6-minute walk distances under 400 meters will receive fisetin for 3 days every 2 weeks over 4 cycles, targeting the cellular senescence that chemotherapy accelerates. This marks a pivotal moment in translational aging research, as senolytics move from promising preclinical data into human applications for functional recovery. The study addresses a critical gap—chemotherapy's lasting impact on physical capacity affects millions of cancer survivors, yet no pharmacological interventions currently exist. Fisetin's dual role as both a senolytic and flavonoid with anti-inflammatory properties makes it particularly intriguing for this application. However, the relatively small sample size and short treatment duration may limit detection of meaningful effects. The 6-minute walk test, while practical, captures only one dimension of physical function. Success here could catalyze larger trials and establish senolytic therapy as a legitimate intervention for age-related functional decline, extending beyond cancer survivorship to broader applications in healthy aging and frailty prevention.